← Back to Search

Imaging Comparison for Age-Related Macular Degeneration (COCO-GA Trial)

N/A

Recruiting

Led By Amitha Domalpally, MD, PhD

Research Sponsored by University of Wisconsin, Madison

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 75 minutes

Awards & highlights

COCO-GA Trial Summary

This trial compares imaging devices to determine which is most accurate at measuring vision loss caused by GA. Patients with GA may join to help improve diagnosis standards.

Who is the study for?

This trial is for individuals over 50 with a specific eye condition called geographic atrophy due to age-related macular degeneration. Participants should have GA areas between 1.25 and 23 mm², which can be either subfoveal or extrafoveal. Those with neovascular AMD, other retinal diseases that could affect the study, or who cannot undergo eye imaging are not eligible.Check my eligibility

What is being tested?

The trial aims to compare three different eye imaging systems: Spectralis FAF, Optos, and Zeiss Clarus 700. It will determine which system's measurements of geographic atrophy area align most closely with the standard care device in patients visiting University Station Eye Clinic.See study design

What are the potential side effects?

Since this study involves non-invasive imaging techniques rather than medication or surgery, side effects are minimal but may include discomfort from bright lights during imaging or temporary visual disturbances after the procedure.

COCO-GA Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 75 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 75 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 75 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Comparison of geographic atrophy area measurements between Clarus and Optos

Comparison of geographic atrophy area measurements by Clarus with standard Spectralis imaging

Comparison of geographic atrophy area measurements by Optos with standard Spectralis imaging

Secondary outcome measures

Prevalence of atrophy outside the standard 30 degrees in Clarus and Optos ultrawide field images

Prevalence of other autofluorescence abnormalities outside the standard 30 degrees in Clarus and Optos ultrawide field images

COCO-GA Trial Design

1Treatment groups

Experimental Treatment

Group I: Fundus autofluorescence (FAF) imagingExperimental Treatment3 Interventions

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Wisconsin, MadisonLead Sponsor

1,189 Previous Clinical Trials

3,169,481 Total Patients Enrolled

Amitha Domalpally, MD, PhDPrincipal InvestigatorUniversity of Wisconsin, Madison

Media Library

Fundus autofluorescence (FAF) imaging Clinical Trial Eligibility Overview. Trial Name: NCT05961332 — N/A

Age-Related Macular Degeneration Research Study Groups: Fundus autofluorescence (FAF) imaging

Age-Related Macular Degeneration Clinical Trial 2023: Fundus autofluorescence (FAF) imaging Highlights & Side Effects. Trial Name: NCT05961332 — N/A

Fundus autofluorescence (FAF) imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT05961332 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this clinical trial for prospective participants?

"Based on the information currently available from clinicaltrials.gov, this medical trial is not recruiting participants at present; it was initially posted on August 1st 2023 and last updated July 18th 2023. Despite that, there are 306 other experiments which require volunteers right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy

2023. "COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05961332.